echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Beliyuzumab is the first treatment protocol approved by the U.S. FDA for the treatment of active lupus nephritis in children

    Beliyuzumab is the first treatment protocol approved by the U.S. FDA for the treatment of active lupus nephritis in children

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, GlaxoSmithKline (GSK) announced that the U.


    Recently, GlaxoSmithKline (GSK) announced that the U.


    Beliyuzumab is the first treatment protocol


    Beliyuzumab is the first treatment protocol


    Steven W.


    Steven W.


    Herson Quinones, vice president of medical affairs for GSK's U.


    Herson Quinones, vice president of medical affairs for GSK's U.


    GSK is continuously improving the quality of life of patients with lupus through continuous exploration, and researching how to protect and prevent organ and kidney damage


    GSK is continuously improving the quality of life of patients with lupus through continuous exploration, and researching how to protect and prevent organ and kidney damage


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.